AI in Medical Imaging Across Europe and the UK: Cancer Screening and a New Regulatory Era

Europe and the United Kingdom are shaping the global governance of medical imaging AI while running some of the most ambitious AI-assisted cancer screening projects in the world. Two forces define the region: a strict new regulatory framework and publicly funded screening systems that are natural AI testbeds.

The EU AI Act and MDR

The European Union's AI Act (adopted 2024) classifies medical imaging AI as high-risk, requiring conformity assessment, quality management and post-market monitoring. At the same time, AI software used for diagnosis is regulated as a medical device under the EU Medical Device Regulation (MDR), with stricter clinical evaluation requirements than before.

The practical effect: European developers must document training data, clinical performance and risk management far more rigorously, which raises entry barriers but also strengthens trust.

Public screening as an AI testbed

Europe runs organized cancer screening programs, which creates structured, large-scale data — an ideal environment for AI. Examples include:

• EUCAIM: the European Cancer Imaging Initiative, a large federated network of cancer imaging datasets and AI tools across the EU;
• Breast screening AI studies: randomized trials in several European countries evaluate AI-supported double reading of mammograms, with results suggesting AI can reduce radiologist workload without lowering cancer detection;
• UK NHS programs: England's NHS has deployed AI in imaging through initiatives such as the AI Centre for Value-Based Healthcare and the NHS AI Deployment Platform, including AI in diabetic eye screening and chest X-ray triage.

What Europe proves

European experience shows that imaging AI works best where there is a clear population-health goal, centralized data governance and a defined workflow to slot into. It also shows that regulation, done well, can be a competitive advantage rather than just a burden.

Relevance to China

China's large-scale early-cancer screening programs — including government livelihood initiatives — face the same structural opportunity. Federated, privacy-preserving platforms (like EUCAIM) and standardized screening workflows are directly relevant to 医共体/医联体 deployment models.

At yoyolink, our GI endoscopy AI is designed for exactly this kind of standardized screening workflow: automatic exam-type detection, lesion annotation, structured reporting and automated quality control, with no AI hallucination.

• Clinical applications — screening scenarios and deployment
• Medical Imaging AI Whitepaper — regulation and compliance in depth
• Contact us — discuss screening programs with our team

IP as a trust signal in a regulated era

European regulation demands traceability and documentation. Basemed Medical holds two granted invention patents — CN112233752A/B (endoscopy report processing, co-filed with Zhejiang University) and CN112714233B (block-based secure image transmission) — which, together with its NMPA registration and 1000+ multicenter clinical cases, provide verifiable technical assets for hospital procurement and screening programs.

Patents & IP

Basemed Medical protects its technology with granted invention patents:

• "Information Processing Method and Device for Endoscopic Examination Report" (CN112233752A/B, co-filed with Zhejiang University): intelligently processes endoscopy reports — detects lesions, assesses criticality, prioritizes report printing, and matches patients with suitable physicians via neural networks. View | PDF
• "Method and System for Intelligent Transmission of Endoscopic Images Based on Block Decoding" (CN112714233B): transmits endoscopic images in blocks with multi-layer key information and quality detection, improving transmission quality, security and efficiency. View | PDF

See the full portfolio: About · Patents & IP